Ticker: STTK

Shattuck Labs, Inc. (NASDAQ: STTK) - Quick take What's happening inside: management has discontinued SL-172154, reallocated spending toward SL-325 (lead DR3 antagonist), plans to start Phase 1 enrollment in Q3 2025, reduced operating expense and cash burn, and executed a Private Placement (Aug 4,...